Bardin P G, Sanderson G, Robinson B S, Holgate S T, Tyrrell D A
Immunopharmacology Group, University Medicine, Southampton General Hospital, UK.
Eur Respir J. 1996 Nov;9(11):2250-5. doi: 10.1183/09031936.96.09112250.
Experimental viral disease studies in volunteers have clarified many aspects of the pathogenesis of human viral disease. Recently, interest has focused on rhinovirus-associated asthma exacerbations, and new volunteer studies have suggested that airway responsiveness (AR) is enhanced during a cold. For scientific, ethical and safety reasons, it is important to use validated methods for the preparation of a virus inoculum and that the particular virological characteristics and host responses should not be altered. We have prepared a new human rhinovirus (HRV) inoculum using recent guidelines and assessed whether disease characteristics (for example, severity of colds or changes in AR) were retained. Studies were conducted in 25 clinically healthy volunteers using a validated HRV inoculum in the first 17 and a new inoculum in the subsequent eight subjects. Severity of cold symptoms, nasal wash albumin levels and airway responsiveness were measured, and the new inoculum was prepared from nasal washes obtained during the cold. The new inoculum was tested using standard virological and serological techniques, as well as a polymerase chain reaction for Mycoplasma pneumoniae. No contaminating viruses or organisms were detected and the methods suggested were workable. Good clinical colds developed in 20 of the 25 subjects and median symptom scores were similar in the validated and new inoculum groups (18 and 17.5, respectively; p=0.19). All subjects shed virus, and there were no differences noted in viral culture scores, nasal wash albumin and rates of seroconversion in the two groups. Although airway responsiveness increased in both groups (p=0.02 and p=0.05), the degree of change was similar. We have performed experimental rhinovirus infection studies and demonstrated similar clinical disease in two inoculum groups. Amplified airway responsiveness was induced; continuing studies will define the mechanisms and suggest modes of treatment.
在志愿者中进行的实验性病毒病研究已阐明了人类病毒病发病机制的许多方面。最近,人们的兴趣集中在鼻病毒相关的哮喘加重方面,新的志愿者研究表明,感冒期间气道反应性(AR)会增强。出于科学、伦理和安全原因,使用经过验证的方法制备病毒接种物很重要,而且特定的病毒学特征和宿主反应不应改变。我们根据最新指南制备了一种新的人鼻病毒(HRV)接种物,并评估了疾病特征(例如感冒的严重程度或AR的变化)是否得以保留。对25名临床健康志愿者进行了研究,前17名使用经过验证的HRV接种物,随后8名受试者使用新的接种物。测量了感冒症状的严重程度、鼻腔冲洗液白蛋白水平和气道反应性,新接种物由感冒期间获得的鼻腔冲洗液制备而成。使用标准病毒学和血清学技术以及肺炎支原体聚合酶链反应对新接种物进行了检测。未检测到污染病毒或生物体,所建议的方法可行。25名受试者中有20人出现了典型的感冒症状,经过验证的接种物组和新接种物组的症状评分中位数相似(分别为18和17.5;p = 0.19)。所有受试者都排出了病毒,两组在病毒培养评分、鼻腔冲洗液白蛋白和血清转化发生率方面均未发现差异。尽管两组的气道反应性均有所增加(p = 0.02和p = 0.05),但变化程度相似。我们进行了实验性鼻病毒感染研究,并在两个接种物组中证明了相似的临床疾病。诱导了气道反应性增强;后续研究将确定其机制并提出治疗方式。